The Role of Microbiome-Immune Crosstalk in Personalized Immunotherapy

The role of microbiome-immune crosstalk in personalized immunotherapy is a rapidly growing research area exploring how the human microbiome influences cancer treatment, particularly immunotherapies like immune checkpoint inhibitors (ICIs). The gut microbiome, a complex ecosystem of microorganisms, plays a crucial role in immune function and inflammation, affecting treatment efficacy. Studies indicate that specific microbial compositions can enhance or hinder immunotherapy responses, making the microbiome a potential biomarker for predicting outcomes and guiding personalized strategies. Patients with diverse microbiomes or beneficial microbial species often respond better to immunotherapy, as microbial metabolites like short-chain fatty acids enhance immune activation. However, dysbiosis has been linked to immune-related adverse events, complicating treatment. Ethical concerns and challenges in standardizing microbiome-based interventions further highlight the complexities of this field. Despite these challenges, integrating microbiome profiling into clinical decision-making holds promise for optimizing personalized immunotherapy and improving patient outcomes in oncology.